시장보고서
상품코드
1526381

세계의 얼굴용 주사제 시장 : 점유율, 규모, 동향, 산업 분석 보고서 : 제품별, 용도별, 최종 용도별, 지역별 정보 예측(2024-2032년)

Global Facial Injectable Market Share, Size, Trends, Industry Analysis Report: Information By Product, By Application, By End-Use, And By Region - Market Forecast, 2024 - 2032

발행일: | 리서치사: Polaris Market Research | 페이지 정보: 영문 117 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

Polaris Market Research의 최근 조사에 따르면 얼굴용 주사제 시장 규모는 2032년까지 336억 3,000만 달러에 달할 전망입니다. 이 보고서는 현재 시장 역학을 상세하게 인사이트하고 미래 시장 성장에 대한 분석을 제공합니다.

비용 효과적인 시술의 도입이 시장 수요를 크게 확대하여 얼굴용 주사제 수요가 급속히 증가하고 있습니다. 이 제품은 비용이 많이 들지 않고 심미적인 강화를 요구하는 소비자에게 쉽게 사용할 수 있는 옵션을 제공하므로 고객층이 넓어지고 시장 전체의 침투율이 높아지고 있습니다.

또한 얼굴용 주사제 수요 증가는 안전과 효능을 보장하고, 보다 폭넓은 소비자에게 있어서 치료가 보다 친숙하고 매력적인 것이 되도록, 규제 당국의 승인이 증가한 것이 배경에 있습니다. 예를 들어, 2023년 5월, AbbVie는 뺨 피부의 부드러움을 개선하는 주비 댐 스킨 바이브의 FDA 승인을 발표했습니다. 이 승인은 얼굴용 주사제의 수용과 혁신의 확대를 강조하고 시장 성장을 가속하며 치료에 대한 소비자의 신뢰를 높이는 것입니다.

또한, 얼굴용 주사제를 포함한 미용 시술의 전체 건수는 꾸준히 증가하고 있으며, 그 결과 시장 수익이 증가하고 있습니다. 예를 들어 미국 성형외과학회(ASPS)에 따르면 2022년 미국에서는 외과적 및 저침습적인 미용 성형 수술이 2,620만 건이 실시되었으며, 2019년부터 19% 증가를 보였습니다. 이러한 외과적 및 저침습적 미용 시술의 동향 증가는 의료 기술의 진보와 주사제의 안전성 프로파일의 개선에 의해 초래됩니다. 이러한 요인의 조합은 시너지 효과를 창출하고 얼굴용 주사제 시장 내 수요를 밀어 올리고 있습니다.

얼굴용 주사제 시장 보고서 하이라이트

히알루론산(HA) 부문은 효과적인 미용 강화를 위해 널리 채택되어 2023년에 가장 큰 시장 점유율을 차지했습니다.

입술증대술은 보다 풍부한 입술, 첨단기술, 다양한 제품 옵션에 대한 소비자 수요에 촉진되어 예측기간 중에 가장 급성장할 전망입니다.

북미는 비침습적인 치료와 제품 혁신으로 미용 시술의 현저한 성장을 경험했으며, 2023년 얼굴용 주사제 시장에서 지배적인 지역이었습니다.

목차

제1장 서론

제2장 주요 요약

제3장 조사 방법

제4장 세계의 얼굴용 주사제 시장 인사이트

  • 용도 스냅샷
  • 얼굴용 주사제 시장 역학
    • 성장 촉진요인과 기회
    • 억제요인과 과제
  • PESTEL 분석
  • 얼굴용 주사제 시장의 용도 동향
  • 밸류체인 분석
  • COVID-19의 영향 분석

제5장 세계의 얼굴용 주사제 시장 : 제품별

  • 주요 조사 결과
  • 소개
  • 콜라겐, PMMA 마이크로 스피어
  • 보툴리눔툭신(보톡스) A형
  • 히알루론산(HA)
  • 칼슘 히드록시아파타이트(CaHA)
  • 폴리-L-락트산(PLLA)
  • 기타

제6장 세계의 얼굴용 주사제 시장 : 최종 용도별

  • 주요 조사 결과
  • 소개
  • 메디스파
  • 피부과 클리닉
  • 병원

제7장 세계의 얼굴용 주사제 시장 : 용도별

  • 주요 조사 결과
  • 소개
  • 페이스 라인 교정
  • 입술의 증대
  • 페이스 리프트
  • 여드름 자취의 치료
  • 지방 위축증의 치료
  • 기타

제8장 세계의 얼굴용 주사제 시장 : 지역별

  • 주요 조사 결과
  • 소개
    • 얼굴용 주사제 시장 평가: 지역별(2019년-2032년)
  • 북미
    • 북미 : 제품별(2019년-2032년)
    • 북미 : 용도별(2019년-2032년)
    • 북미 : 최종 용도별(2019년-2032년)
    • 미국
    • 캐나다
  • 유럽
    • 유럽 : 제품별(2019년-2032년)
    • 유럽 : 용도별(2019년-2032년)
    • 유럽 : 최종 용도별(2019년-2032년)
    • 영국
    • 프랑스
    • 독일
    • 이탈리아
    • 스페인
    • 네덜란드
    • 러시아
    • 기타 유럽
  • 아시아태평양
    • 아시아태평양 : 제품별(2019년-2032년)
    • 아시아태평양 : 용도별(2019년-2032년)
    • 아시아태평양 : 최종 용도별(2019년-2032년)
    • 중국
    • 인도
    • 말레이시아
    • 일본
    • 인도네시아
    • 한국
    • 호주
    • 기타 아시아태평양
  • 중동 및 아프리카
    • 중동 및 아프리카 : 제품별(2019년-2032년)
    • 중동 및 아프리카 : 용도별(2019년-2032년)
    • 중동 및 아프리카 : 최종 용도별(2019년-2032년)
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 이스라엘
    • 남아프리카
    • 기타 중동 및 아프리카
  • 라틴 아메리카
    • 라틴 아메리카 : 제품별(2019년-2032년)
    • 라틴 아메리카 : 용도별(2019년-2032년)
    • 라틴 아메리카 : 최종 용도별(2019년-2032년)
    • 멕시코
    • 브라질
    • 아르헨티나
    • 기타 라틴 아메리카

제9장 경쟁 구도

  • 확대 및 인수 분석
    • 확대
    • 인수
  • 제휴/협업/합의/공개

제10장 기업 프로파일

  • Allergan Aesthetics(AbbVie Inc.)
  • BIOPLUS CO., LTD.
  • Bioxis Pharmaceuticals
  • GALDERMA
  • Ipsen Pharma
  • Merz Pharma
  • Medytox
  • Prollenium Medical Technologies
  • SINCLAIR PLASTIC SURGERY
  • Teoxane
BJH

The global facial injectable market size is expected to reach USD 33.63 billion by 2032, according to a new study by Polaris Market Research. The report "Global Facial Injectable Market Share, Size, Trends, Industry Analysis Report: Information By Product, By Application, By End-Use (MedSpa, Dermatology Clinics, Hospitals), And By Region (North America, Europe, Asia-Pacific, Middle East & Africa, And Latin America) - Market Forecast, 2024 - 2032." gives a detailed insight into current market dynamics and provides analysis on future market growth.

The demand for facial injectables is rapidly increasing due to the introduction of cost-effective procedures that have significantly expanded the market's demand. Products offer accessible options for consumers seeking aesthetic enhancements without high costs, thus widening the customer base and increasing overall market penetration.

Moreover, the growing demand for facial injectables is driven by increased regulatory approvals, that ensures safety, effectiveness and make treatments more accessible and appealing to a broader range of consumers. For instance, in May 2023, AbbVie announced the FDA approval of Juvederm's Skinvive to improve skin smoothness in the cheeks. This approval emphasizes the growing acceptance and innovation in facial injectables, driving market growth and enhancing consumer confidence in treatments.

Furthermore, the overall number of cosmetic procedures, including facial injectables, continues to rise steadily, in turn driving the market revenue. For instance, according to the American Society of Plastic Surgeons (ASPS), in 2022, the United States witnessed 26.2 million surgical and minimally invasive cosmetic procedures, observing a 19% increase since 2019. This rising trends for surgical and minimally invasive cosmetic procedures are driven by advancements in medical technology and improved safety profiles of injectable products. The combination of these factors creates a synergistic effect, boosting demand within the facial injectables market.

Facial Injectable Market Report Highlights

The hyaluronic acid (HA) segment held the largest market share in 2023 due to its widespread adoption for effective cosmetic enhancements.

The lip augmentation is expected to grow fastest over the forecast period, driven by consumer demand for fuller lips, advanced techniques, and diverse product options.

North America was the dominant region in the global facial injectables market in 2023, experiencing significant growth in cosmetic procedures due to non-invasive treatments and product innovations.

The global key market players include Allergan Aesthetics (AbbVie), BIOPLUS CO., LTD., Bioxis Pharmaceuticals, GALDERMA, Ipsen Pharma, Merz Pharma, Medytox, Prollenium Medical Technologies, SINCLAIR PLASTIC SURGERY, and Teoxane

Polaris Market Research has segmented the facial injectable market report based on product, application, end-use and region:

Facial Injectable, Product Outlook (Revenue - USD Billion, 2019 - 2032)

  • Collagen & PMMA Microspheres
  • Botulinum Toxin Type A
  • Hyaluronic Acid (HA)
  • Calcium Hydroxylapatite (CaHA)
  • Poly-L-lactic Acid (PLLA)
  • Others

Facial Injectable, Application Outlook (Revenue - USD Billion, 2019 - 2032)

  • Facial Line Correction
  • Lip Augmentation
  • Face Lift
  • Acne Scar Treatment
  • Lipoatrophy Treatment
  • Others

Facial Injectable, End-Use (Revenue - USD Billion, 2019 - 2032)

  • MedSpa
  • Dermatology Clinics
  • Hospitals

Facial Injectable, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Australia
  • Malaysia
  • Rest of Asia Pacific
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

1.Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Facial Injectable Market Insights

  • 4.1. Facial Injectable Market - Application Snapshot
  • 4.2. Facial Injectable Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. High rate of FDA approvals is a significant catalyst for facial injectables market growth
      • 4.2.1.2. Increasing adoption of facial injectables
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Adverse side effects of facial injectables
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Facial Injectable Market Application Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Facial Injectable Market, by Product

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Facial Injectable Market, by Product, 2019-2032 (USD Billion)
  • 5.3. Collagen & PMMA Microspheres
    • 5.3.1. Global Facial Injectable Market, by Collagen & PMMA Microspheres, by Region, 2019-2032 (USD Billion)
  • 5.4. Botulinum Toxin Type A
    • 5.4.1. Global Facial Injectable Market, by Botulinum Toxin Type A, by Region, 2019-2032 (USD Billion)
  • 5.5. Hyaluronic Acid (HA)
    • 5.5.1. Global Facial Injectable Market, by Hyaluronic Acid (HA), by Region, 2019-2032 (USD Billion)
  • 5.6. Calcium Hydroxylapatite (CaHA)
    • 5.6.1. Global Facial Injectable Market, by Calcium Hydroxylapatite (CaHA), by Region, 2019-2032 (USD Billion)
  • 5.7. Poly-L-lactic Acid (PLLA)
    • 5.7.1. Global Facial Injectable Market, by Poly-L-lactic Acid (PLLA), by Region, 2019-2032 (USD Billion)
  • 5.8. Others
    • 5.8.1. Global Facial Injectable Market, by Others, by Region, 2019-2032 (USD Billion)

6. Global Facial Injectable Market, by End-use

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Facial Injectable Market, by End-use, 2019-2032 (USD Billion)
  • 6.3. MedSpa
    • 6.3.1. Global Facial Injectable Market, by MedSpa, by Region, 2019-2032 (USD Billion)
  • 6.4. Dermatology Clinics
    • 6.4.1. Global Facial Injectable Market, by Dermatology Clinics, by Region, 2019-2032 (USD Billion)
  • 6.5. Hospitals
    • 6.5.1. Global Facial Injectable Market, by Hospitals, by Region, 2019-2032 (USD Billion)

7. Global Facial Injectable Market, by Application

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Facial Injectable Market, by Application, 2019-2032 (USD Billion)
  • 7.3. Facial Line Correction
    • 7.3.1. Global Facial Injectable Market, by Facial Line Correction, By Region, 2019-2032 (USD Billion)
  • 7.4. Lip Augmentation
    • 7.4.1. Global Facial Injectable Market, by Lip Augmentation, By Region, 2019-2032 (USD Billion)
  • 7.5. Face Lift
    • 7.5.1. Global Facial Injectable Market, by Face Lift, By Region, 2019-2032 (USD Billion)
  • 7.6. Acne Scar Treatment
    • 7.6.1. Global Facial Injectable Market, by Acne Scar Treatment, By Region, 2019-2032 (USD Billion)
  • 7.7. Lipoatrophy Treatment
    • 7.7.1. Global Facial Injectable Market, by Lipoatrophy Treatment, By Region, 2019-2032 (USD Billion)
  • 7.8. Others
    • 7.8.1. Global Facial Injectable Market, by Others, By Region, 2019-2032 (USD Billion)

8. Global Facial Injectable Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Facial Injectable Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 8.3. Facial Injectable Market - North America
    • 8.3.1. North America: Facial Injectable Market, by Product, 2019-2032 (USD Billion)
    • 8.3.2. North America: Facial Injectable Market, by Application, 2019-2032 (USD Billion)
    • 8.3.3. North America: Facial Injectable Market, by End-use, 2019-2032 (USD Billion)
    • 8.3.4. Facial Injectable Market - U.S.
      • 8.3.4.1. U.S.: Facial Injectable Market, by Product, 2019-2032 (USD Billion)
      • 8.3.4.2. U.S.: Facial Injectable Market, by Application, 2019-2032 (USD Billion)
      • 8.3.4.3. U.S.: Facial Injectable Market, by End-use, 2019-2032 (USD Billion)
    • 8.3.5. Facial Injectable Market - Canada
      • 8.3.5.1. Canada: Facial Injectable Market, by Product, 2019-2032 (USD Billion)
      • 8.3.5.2. Canada.: Facial Injectable Market, by Application, 2019-2032 (USD Billion)
      • 8.3.5.3. Canada: Facial Injectable Market, by End-use, 2019-2032 (USD Billion)
  • 8.4. Facial Injectable Market - Europe
    • 8.4.1. Europe: Facial Injectable Market, by Product, 2019-2032 (USD Billion)
    • 8.4.2. Europe.: Facial Injectable Market, by Application, 2019-2032 (USD Billion)
    • 8.4.3. Europe: Facial Injectable Market, by End-use, 2019-2032 (USD Billion)
    • 8.4.4. Facial Injectable Market - UK
      • 8.4.4.1. UK: Facial Injectable Market, by Product, 2019-2032 (USD Billion)
      • 8.4.4.2. UK.: Facial Injectable Market, by Application, 2019-2032 (USD Billion)
      • 8.4.4.3. UK: Facial Injectable Market, by End-use, 2019-2032 (USD Billion)
    • 8.4.5. Facial Injectable Market - France
      • 8.4.5.1. France: Facial Injectable Market, by Product, 2019-2032 (USD Billion)
      • 8.4.5.2. France.: Facial Injectable Market, by Application, 2019-2032 (USD Billion)
      • 8.4.5.3. France: Facial Injectable Market, by End-use, 2019-2032 (USD Billion)
    • 8.4.6. Facial Injectable Market - Germany
      • 8.4.6.1. Germany: Facial Injectable Market, by Product, 2019-2032 (USD Billion)
      • 8.4.6.2. Germany.: Facial Injectable Market, by Application, 2019-2032 (USD Billion)
      • 8.4.6.3. Germany: Facial Injectable Market, by End-use, 2019-2032 (USD Billion)
    • 8.4.7. Facial Injectable Market - Italy
      • 8.4.7.1. Italy: Facial Injectable Market, by Product, 2019-2032 (USD Billion)
      • 8.4.7.2. Italy.: Facial Injectable Market, by Application, 2019-2032 (USD Billion)
      • 8.4.7.3. Italy: Facial Injectable Market, by End-use, 2019-2032 (USD Billion)
    • 8.4.8. Facial Injectable Market - Spain
      • 8.4.8.1. Spain: Facial Injectable Market, by Product, 2019-2032 (USD Billion)
      • 8.4.8.2. Spain.: Facial Injectable Market, by Application, 2019-2032 (USD Billion)
      • 8.4.8.3. Spain: Facial Injectable Market, by End-use, 2019-2032 (USD Billion)
    • 8.4.9. Facial Injectable Market - Netherlands
      • 8.4.9.1. Netherlands: Facial Injectable Market, by Product, 2019-2032 (USD Billion)
      • 8.4.9.2. Netherlands.: Facial Injectable Market, by Application, 2019-2032 (USD Billion)
      • 8.4.9.3. Netherlands: Facial Injectable Market, by End-use, 2019-2032 (USD Billion)
    • 8.4.10. Facial Injectable Market - Russia
      • 8.4.10.1. Russia: Facial Injectable Market, by Product, 2019-2032 (USD Billion)
      • 8.4.10.2. Russia.: Facial Injectable Market, by Application, 2019-2032 (USD Billion)
      • 8.4.10.3. Russia: Facial Injectable Market, by End-use, 2019-2032 (USD Billion)
    • 8.4.11. Facial Injectable Market - Rest of Europe
      • 8.4.11.1. Rest of Europe: Facial Injectable Market, by Product, 2019-2032 (USD Billion)
      • 8.4.11.2. Rest of Europe.: Facial Injectable Market, by Application, 2019-2032 (USD Billion)
      • 8.4.11.3. Rest of Europe: Facial Injectable Market, by End-use, 2019-2032 (USD Billion)
  • 8.5. Facial Injectable Market - Asia Pacific
    • 8.5.1. Asia Pacific: Facial Injectable Market, by Product, 2019-2032 (USD Billion)
    • 8.5.2. Asia Pacific.: Facial Injectable Market, by Application, 2019-2032 (USD Billion)
    • 8.5.3. Asia Pacific: Facial Injectable Market, by End-use, 2019-2032 (USD Billion)
    • 8.5.4. Facial Injectable Market - China
      • 8.5.4.1. China: Facial Injectable Market, by Product, 2019-2032 (USD Billion)
      • 8.5.4.2. China.: Facial Injectable Market, by Application, 2019-2032 (USD Billion)
      • 8.5.4.3. China: Facial Injectable Market, by End-use, 2019-2032 (USD Billion)
    • 8.5.5. Facial Injectable Market - India
      • 8.5.5.1. India: Facial Injectable Market, by Product, 2019-2032 (USD Billion)
      • 8.5.5.2. India.: Facial Injectable Market, by Application, 2019-2032 (USD Billion)
      • 8.5.5.3. India: Facial Injectable Market, by End-use, 2019-2032 (USD Billion)
    • 8.5.6. Facial Injectable Market - Malaysia
      • 8.5.6.1. Malaysia: Facial Injectable Market, by Product, 2019-2032 (USD Billion)
      • 8.5.6.2. Malaysia.: Facial Injectable Market, by Application, 2019-2032 (USD Billion)
      • 8.5.6.3. Malaysia: Facial Injectable Market, by End-use, 2019-2032 (USD Billion)
    • 8.5.7. Facial Injectable Market - Japan
      • 8.5.7.1. Japan: Facial Injectable Market, by Product, 2019-2032 (USD Billion)
      • 8.5.7.2. Japan.: Facial Injectable Market, by Application, 2019-2032 (USD Billion)
      • 8.5.7.3. Japan: Facial Injectable Market, by End-use, 2019-2032 (USD Billion)
    • 8.5.8. Facial Injectable Market - Indonesia
      • 8.5.8.1. Indonesia: Facial Injectable Market, by Product, 2019-2032 (USD Billion)
      • 8.5.8.2. Indonesia.: Facial Injectable Market, by Application, 2019-2032 (USD Billion)
      • 8.5.8.3. Indonesia: Facial Injectable Market, by End-use, 2019-2032 (USD Billion)
    • 8.5.9. Facial Injectable Market - South Korea
      • 8.5.9.1. South Korea: Facial Injectable Market, by Product, 2019-2032 (USD Billion)
      • 8.5.9.2. South Korea: Facial Injectable Market, by Application, 2019-2032 (USD Billion)
      • 8.5.9.3. South Korea: Facial Injectable Market, by End-use, 2019-2032 (USD Billion)
    • 8.5.10. Facial Injectable Market - Australia
      • 8.5.10.1. Australia: Facial Injectable Market, by Product, 2019-2032 (USD Billion)
      • 8.5.10.2. Australia: Facial Injectable Market, by Application, 2019-2032 (USD Billion)
      • 8.5.10.3. Australia: Facial Injectable Market, by End-use, 2019-2032 (USD Billion)
    • 8.5.11. Facial Injectable Market - Rest of Asia Pacific
      • 8.5.11.1. Rest of Asia Pacific: Facial Injectable Market, by Product, 2019-2032 (USD Billion)
      • 8.5.11.2. Rest of Asia Pacific: Facial Injectable Market, by Application, 2019-2032 (USD Billion)
      • 8.5.11.3. Rest of Asia Pacific: Facial Injectable Market, by End-use, 2019-2032 (USD Billion)
  • 8.6. Facial Injectable Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Facial Injectable Market, by Product, 2019-2032 (USD Billion)
    • 8.6.2. Middle East & Africa.: Facial Injectable Market, by Application, 2019-2032 (USD Billion)
    • 8.6.3. Middle East & Africa: Facial Injectable Market, by End-use, 2019-2032 (USD Billion)
    • 8.6.4. Facial Injectable Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Facial Injectable Market, by Product, 2019-2032 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Facial Injectable Market, by Application, 2019-2032 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Facial Injectable Market, by End-use, 2019-2032 (USD Billion)
    • 8.6.5. Facial Injectable Market - UAE
      • 8.6.5.1. UAE: Facial Injectable Market, by Product, 2019-2032 (USD Billion)
      • 8.6.5.2. UAE.: Facial Injectable Market, by Application, 2019-2032 (USD Billion)
      • 8.6.5.3. UAE: Facial Injectable Market, by End-use, 2019-2032 (USD Billion)
    • 8.6.6. Facial Injectable Market - Israel
      • 8.6.6.1. Israel: Facial Injectable Market, by Product, 2019-2032 (USD Billion)
      • 8.6.6.2. Israel.: Facial Injectable Market, by Application, 2019-2032 (USD Billion)
      • 8.6.6.3. Israel: Facial Injectable Market, by End-use, 2019-2032 (USD Billion)
    • 8.6.7. Facial Injectable Market - South Africa
      • 8.6.7.1. South Africa: Facial Injectable Market, by Product, 2019-2032 (USD Billion)
      • 8.6.7.2. South Africa.: Facial Injectable Market, by Application, 2019-2032 (USD Billion)
      • 8.6.7.3. South Africa: Facial Injectable Market, by End-use, 2019-2032 (USD Billion)
    • 8.6.8. Facial Injectable Market - Rest of Middle East & Africa
      • 8.6.8.1. Rest of Middle East & Africa: Facial Injectable Market, by Product, 2019-2032 (USD Billion)
      • 8.6.8.2. Rest of Middle East & Africa: Facial Injectable Market, by Application, 2019-2032 (USD Billion)
      • 8.6.8.3. Rest of Middle East & Africa: Facial Injectable Market, by End-use, 2019-2032 (USD Billion)
  • 8.7. Facial Injectable Market - Latin America
    • 8.7.1. Latin America: Facial Injectable Market, by Product, 2019-2032 (USD Billion)
    • 8.7.2. Latin America.: Facial Injectable Market, by Application, 2019-2032 (USD Billion)
    • 8.7.3. Latin America: Facial Injectable Market, by End-use, 2019-2032 (USD Billion)
    • 8.7.4. Facial Injectable Market - Mexico
      • 8.7.4.1. Mexico: Facial Injectable Market, by Product, 2019-2032 (USD Billion)
      • 8.7.4.2. Mexico.: Facial Injectable Market, by Application, 2019-2032 (USD Billion)
      • 8.7.4.3. Mexico: Facial Injectable Market, by End-use, 2019-2032 (USD Billion)
    • 8.7.5. Facial Injectable Market - Brazil
      • 8.7.5.1. Brazil: Facial Injectable Market, by Product, 2019-2032 (USD Billion)
      • 8.7.5.2. Brazil.: Facial Injectable Market, by Application, 2019-2032 (USD Billion)
      • 8.7.5.3. Brazil: Facial Injectable Market, by End-use, 2019-2032 (USD Billion)
    • 8.7.6. Facial Injectable Market - Argentina
      • 8.7.6.1. Argentina: Facial Injectable Market, by Product, 2019-2032 (USD Billion)
      • 8.7.6.2. Argentina.: Facial Injectable Market, by Application, 2019-2032 (USD Billion)
      • 8.7.6.3. Argentina: Facial Injectable Market, by End-use, 2019-2032 (USD Billion)
    • 8.7.7. Facial Injectable Market - Rest of Latin America
      • 8.7.7.1. Rest of Latin America: Facial Injectable Market, by Product, 2019-2032 (USD Billion)
      • 8.7.7.2. Rest of Latin America.: Facial Injectable Market, by Application, 2019-2032 (USD Billion)
      • 8.7.7.3. Rest of Latin America: Facial Injectable Market, by End-use, 2019-2032 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Allergan Aesthetics (AbbVie Inc.)
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. BIOPLUS CO., LTD.
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Bioxis Pharmaceuticals
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. GALDERMA
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Ipsen Pharma
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Merz Pharma
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Medytox
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Prollenium Medical Technologies
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. SINCLAIR PLASTIC SURGERY
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Teoxane
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제